AUTHORS
Rachel Elizabeth Granberg, MD, MPH, Shalini Shenoy, MD2, Melissa Mavers, MD3, Kelsey Busken, MD, MSc4, Moyosoreoluwa M Laditan, MD5, Thomas Pfeiffer, MD6
AFFILIATIONS
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 Washington University School of Medicine, St. Louis, Missouri, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
ABSTRACT
Introduction: Calcineurin inhibitor (CNI) plus methotrexate (MTX) is the standard graft-versus-host disease (GVHD) prophylaxis in pediatric matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo-HCT) for pediatric leukemia. Historically, adult literature has favored tacrolimus (Tac) over cyclosporine (CSA). Pediatric evidence regarding the choice of CNI in MUD allo-HCT and its interaction with serotherapy is limited.
Methods: To assess the impact of CNI choice on transplant outcomes, we performed a secondary analysis of a publicly available Center for International Blood and Marrow Transplant Research dataset (P-6265) including children with acute leukemia undergoing MUD allo-HCT between 2008–2018. All patients received myeloablative conditioning and GVHD prophylaxis with either Tac or CSA in combination with MTX, with or without serotherapy. Overall survival (OS) and relapse-free survival (RFS) were estimated using the Kaplan-Meier method. Cumulative incidence of relapse, treatment-related mortality (TRM), and GVHD were estimated accounting for competing risks. Multivariable Cox proportional hazards models assessed the impact of CNI choice in the absence or presence of serotherapy, adjusting for biologically relevant covariates including disease type, graft type, transplant era, age, donor-recipient sex match, performance status, disease stage and donor age. Transplant center was incorporated as a shared gamma frailty term to account for center effects.
Results: The cohort comprised 860 patients (61% male) with a median age of 13.6 years. Baseline characteristics were well-balanced between Tac+MTX (n=578) and CSA+MTX (n=282) groups, though patients receiving CSA+MTX were significantly younger (median 11.9 vs 14.3 years; p<0.001), more likely to receive a bone marrow graft (85% vs 70%; p<0.001) and to be transplanted in the earlier 2008-2012 era (50% vs 35%; p<0.001). Approximately 40% of both groups received serotherapy (244 and 115 patients, respectively).
In patients who did not receive serotherapy, CSA+MTX was associated with a lower day+100 incidence of grade II-IV acute GVHD (aGVHD) (36% vs 50.8%; p<0.001) and grade III-IV aGVHD (10.4% vs 20.3%; p=0.002) compared to Tac+MTX. The corresponding 3-year incidence of chronic GVHD (cGVHD) was 32.9% vs 49.8% (p<0.001). In multivariable analysis (MVA), CSA+MTX was associated with an HR of 0.73 (p=0.093) for grade II-IV aGVHD, 0.47 (p=0.007) for grade III-IV aGVHD, and 0.61 (p=0.014) for cGVHD compared with Tac+MTX.
Conversely, no differences in GVHD rates were found between CSA+MTX and Tac+MTX in patients who received serotherapy: day+100 incidence of grade II-IV aGVHD was 30.3% vs 34.0% (p=0.5), day+100 grade III-IV was 14.2% vs 12.9% (p=0.8) and 3-year cGVHD rates were 27.7% vs 32.1% (p=0.4). In patients who received serotherapy, MVA confirmed that CSA+MTX was associated with similar risks of grade II-IV aGVHD (HR 0.87; p=0.5), grade III-IV aGVHD (HR 1.1; p=0.8), and cGVHD (HR 0.83; p=0.4) compared with Tac+MTX.
Other transplant outcomes were similar between CNI groups regardless of serotherapy administration. In patients who did not receive serotherapy, 3-year OS (72.5% vs 67.4%; p=0.4) and RFS (65.7% vs 61.0%; p=0.4) were similar between CSA+MTX and Tac+MTX groups. In patients who received serotherapy, 3-year OS was 65.1% vs 69.0% (p=0.3) and 3-year RFS was 60.3% vs 64.7% (p=0.4). There was no difference in the 3-year cumulative incidence of relapse between CSA+MTX and Tac+MTX groups without serotherapy (27.6% vs 23.4%; p=0.3) or with serotherapy (23.2% vs 24.5%; p=0.9). MVA confirmed the absence of differences between groups. Three-year TRM was nominally lower with CSA+MTX compared to Tac+MTX (6.7% vs 15.3%; p=0.014) in patients who did not receive serotherapy, but this effect was not present in MVA (HR 0.60; p=0.13). The corresponding rates in serotherapy recipients were 10.4% and 15.7% (p=0.2).
Conclusion: In this largest-to-date pediatric analysis of CNI choice in MUD allo-HCT, CSA+MTX was associated with a significantly reduced risk of grade III-IV aGVHD and cGVHD compared to Tac+MTX in patients who did not receive serotherapy. These results contrast with available adult data and may reflect differences in target trough attainment, immune reconstitution, thymic function or cytokine milieu in pediatric transplant recipients. While residual confounding cannot be excluded in retrospective analysis, this finding merits prospective validation.
DISCLOSURES
Rachel Elizabeth Granberg, MD, MPH: No relevant conflicts of interest to declare.